A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort | MicrobiomeTrials
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2020-11-23Est. Completion: 2027-12-31
Enrollment target: 83 participants
Locations
Arkansas Children's Hospital, Little Rock, Arkansas, United States
University of California, San Diego, La Jolla, California, United States
University of California, Los Angeles, Los Angeles, California, United States
Stanford University, Palo Alto, California, United States
University of California, Davis, Sacramento, California, United States
University of Florida, Gainesville, Florida, United States
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Washington University in St. Louis, St Louis, Missouri, United States
Duke University Medical Center, Durham, North Carolina, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
Neurology Rare Disease Center, Flower Mound, Texas, United States
Children's Hospital of The King's Daughters, Norfolk, Virginia, United States
Contact
Other microbiome trials you might be interested in